7-Hydroxymethotrexate-d3 (sodium)

• UNSPSC Description:

  7-Hydroxymethotrexate-d3 (sodium) is deuterium labeled 7-Hydroxymethotrexate. 7-Hydroxymethotrexate is a major metabolite of Methotrexate (MTX; HY-14519). Methotrexate, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis[1][2].

• Target Antigen:

  Drug Metabolite; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease;Others

• Field of Research:

  Cancer; Inflammation/Immunology

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@H](C(O)=O)CCC(O)=O)C1=CC=C(N(CC2=NC(C(N)=NC(N)=N3)=C3N=C2O)C([2H])([2H])[2H])C=C1.[Na]

• Molecular Weight:

  496.45

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]L Fahrig, et al. Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. Cancer Chemother Pharmacol. 1989;23(3):156-60.|[3]Ping Guo, et al. Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007 Apr 11;43(5):1789-95.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported